Your browser is no longer supported. Please, upgrade your browser.
Settings
VXRT [NASD]
Vaxart, Inc.
Index- P/E- EPS (ttm)-0.54 Insider Own0.60% Shs Outstand123.98M Perf Week5.95%
Market Cap939.71M Forward P/E- EPS next Y-0.63 Insider Trans-9.02% Shs Float- Perf Month11.98%
Income-63.60M PEG- EPS next Q0.22 Inst Own39.00% Short Float- Perf Quarter-17.35%
Sales1.20M P/S783.09 EPS this Y57.80% Inst Trans5.68% Short Ratio6.05 Perf Half Y12.99%
Book/sh1.65 P/B4.53 EPS next Y-5.10% ROA-30.70% Target Price13.00 Perf Year16.87%
Cash/sh1.49 P/C5.01 EPS next 5Y- ROE-36.10% 52W Range4.86 - 24.90 Perf YTD31.00%
Dividend- P/FCF- EPS past 5Y45.00% ROI-24.60% 52W High-69.31% Beta0.22
Dividend %- Quick Ratio15.30 Sales past 5Y-15.30% Gross Margin- 52W Low57.19% ATR0.37
Employees28 Current Ratio15.30 Sales Q/Q-33.30% Oper. Margin- RSI (14)62.77 Volatility6.17% 5.20%
OptionableYes Debt/Eq0.00 EPS Q/Q-88.90% Profit Margin- Rel Volume2.28 Prev Close7.48
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume3.39M Price7.64
Recom2.00 SMA2010.74% SMA506.64% SMA2004.18% Volume2,949,236 Change2.18%
Nov-02-21Initiated Cantor Fitzgerald Overweight $15
Jun-29-21Downgrade B. Riley Securities Buy → Neutral $13 → $9
Jun-24-21Initiated Jefferies Buy $13
Jun-11-21Initiated Piper Sandler Overweight $18
Aug-12-20Reiterated H.C. Wainwright Buy $7 → $17
Jul-13-20Initiated B. Riley FBR Buy $22
Nov-23-21 08:00AM  
Nov-21-21 06:00AM  
Nov-18-21 04:02PM  
Nov-16-21 08:00AM  
Nov-11-21 04:01PM  
Nov-05-21 06:25AM  
Nov-04-21 05:25PM  
04:01PM  
03:01PM  
Nov-03-21 05:51AM  
Oct-26-21 08:00AM  
Oct-19-21 05:00AM  
Oct-16-21 11:30AM  
Oct-13-21 06:54PM  
Oct-10-21 06:00AM  
Oct-08-21 09:57AM  
07:57AM  
07:34AM  
04:45AM  
Oct-07-21 07:16PM  
04:57PM  
04:13PM  
10:00AM  
07:29AM  
Oct-06-21 02:20PM  
08:00AM  
07:29AM  
Oct-04-21 08:40AM  
Oct-02-21 10:56AM  
Oct-01-21 12:41PM  
Sep-30-21 05:51AM  
Sep-27-21 08:00AM  
Sep-22-21 04:05PM  
Sep-21-21 04:15PM  
Sep-20-21 08:00AM  
Sep-16-21 05:51AM  
Sep-07-21 04:20PM  
Aug-27-21 06:00AM  
Aug-23-21 02:45PM  
09:00AM  
Aug-19-21 04:02PM  
Aug-11-21 08:54AM  
Aug-09-21 01:40PM  
Aug-05-21 06:35PM  
04:02PM  
Aug-02-21 02:41PM  
08:27AM  
08:00AM  
06:00AM  
Jul-29-21 03:05PM  
08:22AM  
Jul-26-21 11:19AM  
Jul-19-21 06:21PM  
03:12PM  
Jul-15-21 06:06AM  
Jul-14-21 08:50AM  
Jul-09-21 12:02PM  
Jul-08-21 10:53AM  
Jul-07-21 08:00AM  
Jun-30-21 10:16AM  
Jun-22-21 05:56AM  
Jun-15-21 11:50AM  
09:56AM  
Jun-14-21 07:35AM  
Jun-11-21 12:01PM  
08:25AM  
Jun-10-21 11:59AM  
Jun-08-21 05:51AM  
Jun-07-21 03:13PM  
09:00AM  
May-27-21 08:00AM  
May-17-21 09:53AM  
May-15-21 06:45AM  
May-14-21 01:18PM  
11:38AM  
May-12-21 09:38AM  
06:03AM  
May-09-21 02:14PM  
May-07-21 08:00AM  
06:10AM  
May-06-21 11:37AM  
06:35AM  
06:00AM  
May-04-21 04:07PM  
09:57AM  
08:00AM  
07:01AM  
05:18AM  
May-03-21 05:06PM  
04:51PM  
11:35AM  
09:15AM  
08:00AM  
05:42AM  
Apr-30-21 06:17PM  
Apr-29-21 08:00AM  
Apr-27-21 06:05AM  
Apr-26-21 08:00AM  
Apr-23-21 08:00AM  
Apr-22-21 08:00AM  
Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which completed Phase I clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. Vaxart, Inc. has a research collaboration agreement with Janssen Vaccines & Prevention B.V. (Janssen) to evaluate the company's proprietary oral vaccine platform for the Janssen universal influenza vaccine program. The company is headquartered in South San Francisco, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Echerd MargaretSVP, Principal Accntng OfficerSep 10Option Exercise1.591,8012,8561,801Sep 13 07:29 PM
Echerd MargaretSVP, Principal Accntng OfficerSep 10Sale9.101,80116,3890Sep 13 07:29 PM
Echerd MargaretSVP, Principal Accntng OfficerAug 10Option Exercise1.581,8012,8521,801Aug 11 06:52 PM
Echerd MargaretSVP, Principal Accntng OfficerAug 10Sale10.001,80118,0100Aug 11 06:52 PM
Tucker SeanSVP, Chief Scientific OfficerAug 10Sale10.205,82859,44651,465Aug 11 06:53 PM
Tucker SeanSVP, Chief Scientific OfficerAug 10Sale10.204,17242,55443,881Aug 11 06:53 PM
Echerd MargaretSVP, Principal Accntng OfficerJul 19Option Exercise1.581,8002,8511,800Jul 21 04:32 PM
Echerd MargaretSVP, Principal Accntng OfficerJul 19Sale8.001,80014,4000Jul 21 04:32 PM
Finney Michael J.DirectorJun 18Option Exercise0.6821,70014,756474,272Jun 21 04:44 PM
Echerd MargaretSVP, Principal Accntng OfficerJun 11Option Exercise1.591,8022,8571,802Jun 14 04:16 PM
Yedid Robert A.DirectorJun 11Option Exercise0.3118,2405,65418,240Jun 14 04:17 PM
Yedid Robert A.DirectorJun 11Sale8.6110,00086,1098,240Jun 14 04:17 PM
Echerd MargaretSVP, Principal Accntng OfficerJun 11Sale8.001,80214,4160Jun 14 04:16 PM
Echerd MargaretSVP, Principal Accntng OfficerJun 09Option Exercise1.9147,55590,88347,555Jun 11 04:17 PM
Echerd MargaretSVP, Principal Accntng OfficerJun 09Sale8.0047,555380,4400Jun 11 04:17 PM
Latour WouterDirectorMay 07Option Exercise1.70100,000170,000100,000May 10 05:05 PM
Latour WouterDirectorMay 07Sale7.13100,000712,7500May 10 05:05 PM
Latour WouterDirectorMay 06Option Exercise1.70100,000170,000100,000May 10 05:05 PM
Latour WouterDirectorMay 06Sale6.54100,000653,8900May 10 05:05 PM
Tucker SeanChief Scientific OfficerMar 16Option Exercise6.491,0066,52948,053Mar 19 05:04 PM
Latour WouterDirectorMar 04Option Exercise0.77150,000115,500150,000Mar 05 04:03 PM
Latour WouterDirectorMar 04Sale6.04150,000906,4500Mar 05 04:03 PM